BioinformaticsCancerDiseasesMedicinePersonalizedMedicinePress releasesProjectsScience AreaSoftware DevelopmentUncategorized
Waldsassen – BioVariance has finished the development of the platform OncoVariant for the interpretation of genetic variants in cancer patients. Thereby, the crucial search for suitable drugs is simplified and accelerated significantly.
BioVariace has received a financial grant for a pioneering research project to calculate personalized dosages for psychotherapeutic drugs based on patient´s unique individual genetic biomarkers. The project “Knowledge for personalized medicine in psychiatric application” will be co-funded by the Bavarian Ministry of Economic Affairs and further project partners includes the Institute of Pharmacy of the University of Würzburg as well as the Center for Mental Health of the University Hospital of Würzburg.